Filter By Category
Archives
Share on -
DUBERMATINIB
Generic Name: DUBERMATINIB
ABSTRACT -
Dubermatinib is an investigational small-molecule inhibitor of AXL receptor tyrosine kinase studied in hematologic malignancies and solid tumors.
DOSAGE -
No approved dosage. Oral dosing is defined by clinical trial protocol and dose-escalation cohort.
SIDE EEFECTS -
- Nausea or vomiting
- Diarrhea
- Fatigue
- Anemia or thrombocytopenia
- Elevated liver enzymes
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Rash or pruritus
- Urticaria
- Facial swelling
- Severe hypersensitivity (rare)
DRUG INTERACTIONS-
- CYP3A inhibitors/inducers may alter exposure
- QT-prolonging drugs may require caution if protocol-specified
- Other myelosuppressive therapies may increase cytopenias
PREAUTONS–
- Monitor CBC, hepatic enzymes, and ECG parameters when protocol requires
- Use contraception during and after treatment per study protocol
- Avoid use outside clinical trials
WARNINGS –
- Investigational agent; safety and efficacy not established
- Potential hepatic, hematologic, and gastrointestinal toxicity
Share on -
. Developed by